In a 16-station rotary tablet press equipped with a forced feeder, direct compression of Qinglan Granules Veterinary Grade API becomes reproducible only when the granule size distribution remains within a D50 of 75–150 µm and a D90 below 250 µm, as confirmed by laser diffraction using ISO 13320:2020. The tablet press operates with a precompression force of 5–8 kN and a main compression force of 12–22 kN. Increasing main compression beyond 22 kN produces capping and edge chipping because the botanical granular bed exhibits low elastic recovery after plastic deformation. Tablets intended for oral administration to swine or poultry are compressed to a breaking force of 50–90 N when tested according to USP <1217>. Values below 50 N fail film-coating pan durability. Values above 110 N extend disintegration beyond the 30-minute limit in USP <701>. Lubrication with 0.5% w/w magnesium stearate is limited to 3–5 minutes in a bin blender at 10 rpm. Blending beyond 8 minutes decreases tensile strength by 15–30% due to hydrophobic surface coverage on the granule particles. Feed moisture is controlled between 2.0% and 5.0%. Below 2.0%, lamination appears at the tablet edges. Above 5.0%, picking on concave punches interrupts press operation. Content uniformity follows USP <905>, with an acceptance value of ≤15.0 for a 10 mg label claim. Ejection force above 800 N indicates insufficient die wall lubrication and accelerates tooling wear.

Direct compression is preferred over wet granulation when the supplier batch already contains a granulated matrix resistant to attrition. Roll compaction becomes necessary when the incoming granule has a fines fraction below 75 µm exceeding 20% w/w. The roller compactor operates at a roll pressure of 30–50 bar, a roll gap of 2.0–3.0 mm, and a post-milling screen size of 0.8–1.2 mm. These parameters produce compacted granules with a Carr index below 20% and a Hausner ratio below 1.25, which are suitable for high-speed tableting. Sodium starch glycolate above 8.0% w/w should be avoided because rapid disintegration in contact with the acidic fraction of the extract causes premature tablet splitting during coating. A film coating with 3.0–4.0% weight gain using hydroxypropyl methylcellulose is applied in a perforated pan at 45–55°C inlet air. Higher inlet air above 60°C darkens the tablet surface and increases assay-related degradation. The press hopper is maintained at 35–40% RH. Prolonged exposure at RH above 60% increases granule moisture by 2–3% within 30 minutes and shifts tablet weight variation outside the acceptance limit.

Which Filtration and Sterilization Parameters Govern Injectable Qinglan Granule Solutions?

Because aqueous extracts may contain heat-labile polyphenolics, terminal sterilization at 121°C for 15 minutes is not assigned as a default cycle. Aseptic filtration through a 0.22 µm PVDF membrane is selected when the pre-filter turbidity remains below 10 NTU. A pre-filter capsule with a 0.45 µm polypropylene membrane removes coarse dispersions and extends the life of the sterilizing membrane from 10 L/m² to 40–60 L/m² at 20°C. The solution is compounded in Water for Injection at pH 6.0–7.5. Below pH 5.0, aglycone precipitation produces visible particles. Above pH 8.0, oxidative browning accelerates. Nitrogen sparging reduces dissolved oxygen to <0.5 mg/L before filling. Residual oxygen above this value accelerates color change during storage at 25°C. Osmolality is adjusted to 280–320 mOsm/kg with sodium chloride or dextrose. Particulate matter testing is conducted against USP <788> Method 1, with not more than 6000 particles ≥10 µm and 600 particles ≥25 µm per container. Bacterial endotoxin limits are derived from USP <85>. For a 10 mg/kg parenteral dose in swine, a limit of ≤0.5 EU/mg API is conservative for intravenous administration. Filter compatibility is determined by reflux testing at 37°C for 24 hours. Adsorption of phenolic acids onto PVDF can reduce assay by 5–10% unless the membrane is preflushed with a 0.1% w/v solution of the same extract.

Autoclavable injectable presentations of this specific granule are not assumed. Published data for the botanical granule in 121°C saturated-steam cycles are limited. If terminal sterilization is required for a non-sterile manufacturing facility, a pilot-scale heat challenge at 110°C for 20 minutes may be tested. The formulation must then be evaluated for precipitate formation and marker retention. Aseptic processing therefore requires a Grade B environment with Grade A filling. Fill volume accuracy is maintained at ±2% using a rotary piston pump. Filters are integrity-tested by forward-flow bubble point before and after filling. A pore-size-dependent bubble point of ≥0.8 bar is used for a wet PVDF membrane. Filled vials are sealed with bromobutyl rubber stoppers and aluminum overseals. Headspace oxygen is maintained below 0.2% after nitrogen overlay. This route is reserved for injectable solutions only. Suspensions for injection are not recommended because the granule solids settle in small-volume parenteral containers and cannot be resuspended uniformly.

On an intermittent-motion dosator capsule filler, the filling weight precision for a size 1 hard gelatin capsule containing 250 mg of the granulated extract is controlled by the tapped density of the blend. The tapped density is maintained at 0.45–0.65 g/mL. The capsule filling area is conditioned at 21–25°C and 35–40% RH. The gelatin shell equilibrium moisture is 13–16% w/w. The fill blend is dried to <6.0% w/w moisture. If the room humidity exceeds 60% RH for more than 30 minutes, moisture migration softens the capsule shell and produces dimpling, telescoping, and fill weight drift outside ±5%. Powder flow is improved with 0.2% w/w sodium stearyl fumarate. Magnesium stearate at 0.5% w/w is acceptable only when mixed for 3 minutes at low shear. Longer mixing lowers dissolution below 80% at 30 minutes. Immediate-release capsules are tested according to USP <711> Apparatus II at 50 rpm in 900 mL of pH 6.8 phosphate buffer. The requirement is Q=80% at 30 minutes. The granulated API typically releases more than 85% within 20 minutes when croscarmellose sodium is present at 3–5% w/w. Content uniformity by USP <905> requires an acceptance value of ≤15.0. Dosator pin speed beyond 70 strokes per minute with granule D90 above 300 µm produces fill weight variation outside this limit. Hard gelatin capsules are preferred over hypromellose shells when the filling room operates at 40% RH. Below 30% RH, gelatin becomes brittle and splitting occurs during opening. Hypromellose shells may require higher fill-line lubrication under the same conditions.

When Qinglan Granules Are Dispersed in Drinking Water Systems

In drinking-water proportioning pumps, the stock solution is normally prepared at 1:100 dilution and then metered at 1:1000 to 1:2000 final dilution. The stock solution must remain free of suspended solids that settle in diaphragm pump chambers and cause air-lock. Particle size of the dispersible granule after reconstitution is set at D90 ≤180 µm, measured by wet laser diffraction using ISO 13320:2020. Particles above 250 µm settle in nipple drinker lines and produce uneven dose intake across a barn. Sedimentation volume after 2 hours at 25°C should not exceed 0.5% v/v. When this limit is exceeded, xanthan gum at 0.1–0.3% w/v or microcrystalline cellulose/sodium carboxymethylcellulose at 0.5–1.0% w/v is incorporated. Water hardness above 250 mg/L calcium carbonate equivalent reduces the surface charge of suspended extract particles and induces coagulation. Citric acid at 0.05–0.2% w/w is added only when the farm water analysis confirms this hardness. The pre-mixing tank includes a high-shear disperser operated at 1,500–3,000 rpm for 10–15 minutes. Dispersion beyond 30 minutes increases foam volume and reduces headspace. Stock solution microbiological stability is limited to 24 hours at 25°C and 48 hours at 5°C. In non-preserved systems, bacterial growth can exceed 10² CFU/mL after these periods. Medicated drinking water is assigned a 6-hour consumption window. Longer residence times increase biofilm interaction and decrease water intake. The formula remains an immediate-release oral solution. No controlled-release action or injectable equivalency should be inferred from this route.

For powder and granule sachets intended for manual dilution in stock tanks, the product is packaged in 1–5 kg foil-lined pouches with a desiccant. The water vapor transmission rate of the pouch is specified below 0.1 g/m²/day at 38°C/90% RH. The granule blend includes 2.0% w/w colloidal silicon dioxide to prevent caking when stored in unopened containers at 30°C. If the product is stored at 40°C/75% RH for more than 3 months, caking increases the median particle size to D50 above 200 µm and reduces dispersibility. A dry flow test using a funnel with a 10 mm orifice is used as an incoming QC check. Discharge time for 100 g should be <20 seconds. When the water source contains chlorine at 1–3 mg/L, a short contact time of <1 hour is specified because free chlorine oxidizes the extract and lowers active marker content. Sodium thiosulfate at 0.005% w/w may be added only when confirmed by a chlorine assay.

Carry-Over Thresholds and Pelleting Stability in Medicated Premix Lines

The sequence of ingredient addition in premix production determines whether the 10% w/w granular API premix achieves a coefficient of variation below 5.0% after 10 minutes in a double-ribbon mixer at 25 rpm. The granulated API is first blended with a hydrophobic carrier such as ground rice hulls or calcium carbonate at a 1:10 ratio. This step reduces electrostatic adhesion when relative humidity is below 30%. Tribo-charging at low RH causes granule loss to mixer surfaces and low assay recovery. The intermediate premix is diluted with ground corn or wheat middlings to a final inclusion of 1:1000 or 1:2000 in complete feed. The mixer is validated according to ISO 6497:2002. The lower confidence interval of assay results must be ≥90% label claim. The upper limit must be ≤110% label claim. After production, cleaning is performed with ground limestone at 10% of mixer capacity. If carry-over exceeds 1.0% of the previous batch active concentration, the flush is repeated. Feed pelleting is limited to a conditioner temperature of 75–85°C with 15–30 seconds residence time. Assay loss of the granulated extract in this range is typically below 5.0%. Above 90°C, assay loss may exceed 10% and pellet durability decreases due to heat-induced binder interactions. Molasses and sodium bentonite are not recommended in the same premix because both increase moisture retention and cause clumping during storage. The finished premix is stored in multi-wall paper bags with a polyethylene liner at ≤25°C and ≤60% RH. A 12-month retest is assigned only when real-time data from three production lots support the stability. The medicated feed itself is consumed within 6 weeks of mixing. Longer storage in farm bins can stratify the granule fraction if the feed is poured through a drop tube rather than a mass-flow hopper.

Dryer and pelleting line trials indicate that the granulated API remains stable when the feed exits the conditioner at 14–16% moisture and is dried to 12% moisture before cooling. Moisture above 16% at the pellet die promotes molding of lactose-free formulations after cooling. A reverse-cleaning filter on the pellet cooler reduces cross-contamination with other medicated premix batches. The same filter is replaced when pressure drop rises by 25% above baseline. Sampling points for mixer validation are selected according to ISO 6497:2002. The assay method for the marker constituent is validated for specificity against the carrier. Near-infrared methods should not replace HPLC or UPLC confirmation unless a standard curve of 0.5–5.0 mg/L is generated for each carrier lot.

Before suspension rheology is fixed, the wetting behavior of the granule surface in an oral drench vehicle determines the sedimentation volume. The formula is based on a 5% w/v granule dispersion in a buffered aqueous vehicle at pH 6.2–6.8. The vehicle is preserved with 0.1% w/w sodium benzoate and 0.05% w/w potassium sorbate when the product is not supplied as a single-dose drench. Wetting is accomplished with 0.05–0.2% w/w polysorbate 80. Surfactant concentrations above 0.5% w/w generate foam and reduce the dose accuracy of automatic drench guns. The vehicle viscosity is adjusted to 300–700 mPa·s at 25°C using xanthan gum or carbomer. Below 300 mPa·s, sedimentation is rapid. Above 700 mPa·s, the product cannot pass through a 5 mL automatic drench gun without inconsistent delivery. The fill volume for sheep or goat dosing is 5.0 mL per 20 kg body weight. The drench gun is verified to deliver ±2% of target volume. The suspension must remain homogeneous for 30 minutes after shaking, measured by a sedimentation volume ratio F of 0.9–1.0. Bitter taste masking uses 0.2% w/w sodium saccharinate and 0.1% w/w anethole. These are included only after organoleptic testing in the target species. The water activity of the finished suspension is typically 0.90–0.97. If it exceeds 0.97, preservative efficacy testing against USP <51> is required for oral products with aqueous vehicles. The product is packaged in amber PET bottles because UV exposure for 14 days reduces the active marker by more than 10%. Light protection is mandatory from bulk holding through finished storage. Published long-term stability data for this specific granulated extract in preserved oral drench form are limited. A shelf life beyond 24 months should not be assigned without bracketing studies.